Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)
Publication
, Conference
Kadia, TM; Benton, C; Erba, HP; Gandhi, M; Levy, MY; Percival, M-EM; Ulrickson, M; Yimer, H; Yu, M; Chen, Z; Wang, J; Li, M; Ahmad, M ...
Published in: Blood
November 15, 2022
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2022
Volume
140
Issue
Supplement 1
Start / End Page
11659 / 11660
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Kadia, T. M., Benton, C., Erba, H. P., Gandhi, M., Levy, M. Y., Percival, M.-E., … Zhai, Y. (2022). Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS). In Blood (Vol. 140, pp. 11659–11660). American Society of Hematology. https://doi.org/10.1182/blood-2022-162627
Kadia, Tapan M., Christopher Benton, Harry P. Erba, Mitul Gandhi, Moshe Y. Levy, Mary-Elizabeth M. Percival, Matthew Ulrickson, et al. “Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS).” In Blood, 140:11659–60. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-162627.
Kadia TM, Benton C, Erba HP, Gandhi M, Levy MY, Percival M-EM, et al. Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS). In: Blood. American Society of Hematology; 2022. p. 11659–60.
Kadia, Tapan M., et al. “Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS).” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 11659–60. Crossref, doi:10.1182/blood-2022-162627.
Kadia TM, Benton C, Erba HP, Gandhi M, Levy MY, Percival M-EM, Ulrickson M, Yimer H, Yu M, Chen Z, Wang J, Li M, Ahmad M, Yang D, Zhai Y. Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS). Blood. American Society of Hematology; 2022. p. 11659–11660.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2022
Volume
140
Issue
Supplement 1
Start / End Page
11659 / 11660
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology